Cantor Fitzgerald Brokers Boost Earnings Estimates for MIRM

Key Points

• Analysts at Cantor Fitzgerald have increased their FY2025 earnings estimate for Mirum Pharmaceuticals from ($1.13) to ($1.00) per share.
• Following several upgrades from financial institutions, Mirum Pharmaceuticals now has an average rating of "Buy" with a consensus target price of $72.00.
• In its latest earnings report, Mirum exceeded expectations with a 64.1% increase in revenue, reporting $127.79 million against an anticipated $107.91 million.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for Mirum Pharmaceuticals in a research report issued on Thursday, August 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($1.00) per share for the year, up from their prior forecast of ($1.13). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. Cantor Fitzgerald also issued estimates for Mirum Pharmaceuticals' FY2026 earnings at ($0.38) EPS.

A number of other equities analysts have also issued reports on the stock. Evercore ISI raised their price target on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday. Raymond James Financial reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Thursday. Wall Street Zen raised shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. JMP Securities lifted their price objective on Mirum Pharmaceuticals from $79.00 to $81.00 and gave the company a "market outperform" rating in a research note on Thursday. Finally, HC Wainwright upped their target price on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $72.00.

Mirum Pharmaceuticals Trading Up 0.3%

Mirum Pharmaceuticals stock opened at $59.97 on Monday. The stock has a 50-day moving average price of $50.86 and a 200 day moving average price of $47.17. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -49.56 and a beta of 0.94. Mirum Pharmaceuticals has a 52 week low of $36.86 and a 52 week high of $61.00. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.19. The company had revenue of $127.79 million during the quarter, compared to analysts' expectations of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%. The firm's revenue was up 64.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.52) EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MIRM. Geode Capital Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock valued at $39,016,000 after acquiring an additional 7,147 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Mirum Pharmaceuticals by 8.1% in the 4th quarter. Russell Investments Group Ltd. now owns 25,960 shares of the company's stock valued at $1,073,000 after purchasing an additional 1,945 shares during the last quarter. Invesco Ltd. lifted its holdings in Mirum Pharmaceuticals by 5.2% in the 4th quarter. Invesco Ltd. now owns 299,279 shares of the company's stock valued at $12,375,000 after purchasing an additional 14,747 shares in the last quarter. Legal & General Group Plc boosted its stake in Mirum Pharmaceuticals by 3.5% during the 4th quarter. Legal & General Group Plc now owns 40,820 shares of the company's stock worth $1,688,000 after purchasing an additional 1,389 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Mirum Pharmaceuticals by 67.5% during the fourth quarter. Renaissance Technologies LLC now owns 101,248 shares of the company's stock worth $4,187,000 after buying an additional 40,800 shares in the last quarter.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $55.25, for a total transaction of $2,210,000.00. Following the completion of the transaction, the chief executive officer directly owned 138,641 shares in the company, valued at approximately $7,659,915.25. This represents a 22.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jolanda Howe sold 10,000 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the sale, the senior vice president owned 2,426 shares in the company, valued at approximately $140,708. This trade represents a 80.48% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,041 shares of company stock valued at $2,840,624. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.